
What PCPs Should Know About Treating Patients With Diabetes
Primary care plays a crucial role in the treatment of diabetes. Primary care physicians (PCPs) are typically the first line of health care for patients with type 2 diabetes.
But PCPs are often tasked with managing treatment for type 1 diabetes as well, particularly in areas with limited access to endocrinologists and other specialists in diabetes care.
To learn more about how primary care providers handle some of the challenges of treating individuals with diabetes, Medscape Medical News turned to Brent Smith, MD, a family physician in Greenville, MS, board member of the American Association of Family Physicians.
Below are Smith's responses to key questions about diabetes care:
Q: How do you tailor treatment to patients of different socioeconomic backgrounds and health literacy levels?
A: When treating my diabetic patients, ideally, we would treat according to best practices first and adjust from there.
However, in reality, I find myself treating first by what the patient can afford — through the vagaries of payor coverage and then their own financial resources — then by health literacy. The best treatment plan is worthless if the patient cannot understand or implement it.
Last comes best practices. Often, I have had to adjust treatment plans to suboptimal choices because that is what the patient can afford and (at times) to keep the treatment plan reasonable to what the patient can accommodate in their life.
Q: What is a go-to strategy for patients struggling to maintain good glycemic control despite the use of multiple medications?
A: There really isn't a one-size-fits-all approach. The hallmarks of success are simplicity, and the challenge is finding that.
With dietary choices, I try to make the advice simple. Shop from the outside aisles of the store — where fresh food is housed — and try to avoid the middle aisles, where the processed grains and sugars are kept.
When looking at carbohydrates, I encourage them to avoid white foods, such as white rice, white bread, potatoes, and sugar, and try to pick things that are brown — whole grain bread, brown or wild rice, and sweet potatoes. We always encourage more exercise, but that often involves advising how to work it into their life schedule without it being overwhelming.
Q: How are glucagon-like peptide 1 (GLP-1) medications for diabetes and weight loss affecting the way you treat patients?
A: Ironically, the 'new' [GLP-1] weight loss drugs have been around for decades but have just recently achieved prominence. However, what they have changed is a renewed emphasis on weight loss and lifestyle change rather than the emphasis on adding on medications.
Q: How do you coordinate care with endocrinologists, dietitians, and other specialists for more complex patient cases?
A: I live in a rural area, about 2 hours away from an endocrinologist. I refer my type 1 diabetics for assistance but not commonly with my regular patients. Dietitians are great, but in our setting, they are typically hospital-employed, so their main role is educating diabetics in the hospital setting.
Q: What is something that you wish more PCPs understood or put into practice when it comes to treating individuals with diabetes?
A: My biggest request of anyone treating diabetic patients would be to remember 'reality' vs what the book says.
A good example of this for me is the expectation that all patients with diabetes should be checking their blood sugar daily. It is a painful and expensive hassle that we expect patients to take on without question. However, we rely on A1c for grading control.
Until continuous glucose monitors fully take over the market, unless a patient is taking insulin, I only ask them to check a fingerstick if they are feeling ill or worried their blood sugars might be very high or very low.
If we aren't asking them to make regular changes based on their fingerstick readings and their ability to make those changes in lifestyle and diet is often very limited, then why are we asking them to use glucometers daily?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
2 hours ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.


Medscape
3 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.


Washington Post
4 hours ago
- Washington Post
New York lawmakers approve bill that would allow medically assisted suicide for the terminally ill
ALBANY, N.Y. — Terminally ill New Yorkers would have the legal ability to end their own lives with pharmaceutical drugs under a bill passed Monday in the state Legislature. The proposal, which now moves to the governor's office, would allow a person with an incurable illness to be prescribed life-ending drugs if he or she requests the medication and gets approval from two physicians. A spokesperson for New York Gov. Kathy Hochul said she would review the legislation.